Wattal Sushant, Rao Mugula Sudhakar, Chandra Gs Naveen, Razak U K Abdul, Shetty K Ranjan
Registrar, Department of Cardiology, KMC , Manipal, Karnataka, India .
Assistant Professor, Department of Cardiology, KMC , Manipal, Karnataka, India .
J Clin Diagn Res. 2017 Feb;11(2):FD03-FD04. doi: 10.7860/JCDR/2017/24633.9418. Epub 2017 Feb 1.
Drug induced cardiac tamponade is rare. Therapy for imatinib resistant Chronic Myeloid Leukaemia (CML) is an emerging challenge in clinical haematology. For such cases treatment with second line tyrosine kinase inhibitors like dasatinib has resulted in improved outcomes. Dasatinib is a second line BCR-ABL tyrosine kinase inhibitor used in the treatment of Imatinib resistant or Imatinib intolerant CML. Dasatinib has been reported to cause severe pericardial effusions in 1% of all patients in clinical studies. We report here a case of Dasatinib induced cardiac tamponade in whom all other causes of pericardial effusion were excluded and whose clinical symptoms as well as effusion showed no recurrence one month after the drug was stopped.
药物性心脏压塞较为罕见。伊马替尼耐药的慢性髓性白血病（CML）的治疗是临床血液学中一个新出现的挑战。对于此类病例，使用达沙替尼等二线酪氨酸激酶抑制剂进行治疗已使治疗效果得到改善。达沙替尼是一种二线BCR-ABL酪氨酸激酶抑制剂，用于治疗伊马替尼耐药或不耐受的CML。临床研究报道，在所有患者中，有1%的患者使用达沙替尼后出现严重心包积液。我们在此报告一例达沙替尼诱发的心脏压塞病例，该病例排除了心包积液的所有其他病因，且在停药一个月后临床症状及积液均未复发。
